Brainomix Announces New Partnership with Boehringer Ingelheim to Develop AI-Powered Radiomic Software for Automated Assessment of Solid Tumor Cancer
The collaboration will focus on the development of AI tools to improve the accuracy and standardization of tumor measurement in lung cancer trials OXFORD, England, Feb. 1, 2022 /PRNewswire/
Prnewswire Brainomix Boehringer Ingelheim Eric Greveson Florian Gantner University Of Oxford Drug Administration
Source: finanznachrichten.de